Evidence map›Paper›PMID 40389436›Full record

ArticleNature communications2025

Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma.

Kim Wong, Justin A Bishop, Ilan Weinreb, Marialetizia Motta, Martin Del Castillo Velasco-Herrera, Emanuele Bellacchio, Ingrid Ferreira, Louise van der Weyden, Jacqueline M Boccacino, Antonella Lauri and 18 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Kim WongExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-0984-1477
Justin A Bishop *Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ilan Weinreb *Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada.
Marialetizia Motta *Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Martin Del Castillo Velasco-HerreraExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0001-5956-0211
Emanuele BellacchioMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Ingrid FerreiraExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-4321-5250
Louise van der WeydenExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-0645-1879
Jacqueline M BoccacinoExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0001-6813-5217
Antonella LauriMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0003-2260-182X
Giovannina RotundoMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Andrea CiolfiMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-6191-0978
Saamin CheemaExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0002-5297-2042
Rebeca Olvera-LeónExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Victoria OffordExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Alastair DroopExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0001-7695-7480
Ian VermesExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Michael AllgäuerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4518-7887
Martin HyrczaDepartment of Pathology and Laboratory Medicine, University of Calgary, Arnie Charboneau Cancer Institute, Calgary, AB, Canada.
Elizabeth AndersonExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Katie SmithExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Nicolas de Saint AubainDepartment of Pathology, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles, Brussels, Belgium.
Carolin MoglerSchool of Medicine and Health, Technical University Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3400-7254
Albrecht StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1001-103X
Mark J ArendsEdinburgh Pathology, Cancer Research UK Scotland Centre, The University of Edinburgh, Institute of Genetics and Cancer, Edinburgh, UK.ORCID http://orcid.org/0000-0002-6826-8770
Thomas BrennDepartments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan, USA.
Marco TartagliaMolecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-7736-9672
David J AdamsExperimental Cancer Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK. da1@sanger.ac.uk.ORCID http://orcid.org/0000-0001-9490-0306

Funding

RCUK | Medical Research Council (MRC) MR/V000292/1Wellcome TrustWellcome Trust (Wellcome) 108413/A/15/D
6 · The paper itself

Abstract

Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) of the salivary gland are rare tumours that can be difficult to distinguish from each other and other salivary gland tumour subtypes. Using next-generation sequencing, we identify a recurrent FBXW11 missense mutation (p.F517S) in BCA that is mutually exclusive with the previously reported CTNNB1 p.I35T gain-of-function (GoF) mutation with these mutations collectively accounting for 94% of BCAs. In vitro, mutant FBXW11 is characterised by defective binding to β-catenin and higher protein levels within the nucleus. This is consistent with the increased nuclear expression of β-catenin and activation of the Wnt/β-catenin pathway. The genomic profiles of BCAC are distinct from BCA, with hotspot DICER1 and HRAS mutations and putative driver mutations affecting PI3K/AKT and NF-κB signalling pathway genes. These findings have important implications for the diagnosis and treatment of BCA and BCAC, which, despite histopathologic overlap, may be unrelated entities.

Indexed as

Adenomabeta CateninF-Box ProteinsSalivary Gland NeoplasmsWnt Signaling PathwayAdenocarcinomaCell Line, TumorFemaleHumansMaleMiddle AgedMutationMutation, Missensebeta CateninCTNNB1 protein, humanF-Box Proteins

Identifiers

PMID40389436
PMCPMC12089348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.